How AfterSlim is formulated.
AfterSlim is a dietary supplement, not a prescription drug. The standards we hold the formula to are not lower because of that. This page documents the methodology, the references behind each ingredient choice, and the testing every batch goes through. The mechanism story lives on The Science.
How we choose strains
Each probiotic strain in AfterSlim has to clear three criteria before going into the capsule.
- Mechanism clarity Published research must explain how the strain interacts with the gut barrier, the mucus layer, or short-chain fatty acid production. We don't include strains based on marketing claims.
- Dose-response evidence Human trials must establish a working dose. We formulate at or above that dose, not below it.
- Survivability The strain has to survive room-temperature shipping and stomach acid. We use enteric-coated, moisture-locked capsules to keep CFU counts intact at the point of absorption.
How we choose prebiotics
A probiotic without its fuel is a seed without soil. Every strain is paired with a prebiotic fiber that human studies show feeds it.
- Chicory root inulin Pairs with Akkermansia muciniphila. Cani et al. (2017) reported inulin can roughly triple Akkermansia abundance over 8 weeks.
- Resistant starch Colonic fermentation fuel that converts to butyrate, supporting the gut barrier and satiety between GLP-1 doses.
Third-party testing
Every batch of AfterSlim is tested by an independent ISO 17025-accredited laboratory for:
- Strain identity and CFU potency at time of release and at end-of-shelf-life
- Heavy metals (lead, arsenic, cadmium, mercury) below USP limits
- Microbial safety, with no detectable pathogens
- Pesticide and gluten contamination
Test reports ship with every order, and on request at support@afterslim.com.
Regulatory boundaries
AfterSlim is not a GLP-1 agonist, does not affect blood sugar through the GLP-1 pathway, and is not a substitute for prescribed medication. It is a companion protocol for the gut while a GLP-1 medication does its work.
Key references
- Cani PD, de Vos WM. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Frontiers in Microbiology, 2017.
- Depommier C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine, 2019.
- Yoon HS, et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nature Microbiology, 2021.
- Plovier H, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine, 2017.
- Hagi T, Belzer C. The interaction of Akkermansia muciniphila with host-derived substances. Applied Microbiology and Biotechnology, 2021.
- Cani PD, et al. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nature Reviews Gastroenterology & Hepatology, 2022.
Information on this page is for educational purposes and not a substitute for medical advice. Always consult your healthcare provider before starting any supplement, especially if you are on prescription medication, pregnant, or nursing.